Form 4 for GMED GLOBUS MEDICAL INC

Accepted 2023-09-06 00:00:00 ET · period of report 2023-09-01 · accession 0001209191-23-048412 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-09-06	2023-09-01	GMED	DeFord John A	Dir	A - Grant	—	+15.6K	15.6K	New	—
D	2023-09-06	2023-09-01	GMED	DeFord John A	Dir	A - Grant	$0.00	+15.0K	15.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Class A Common Stock	2023-09-01	A	A	15,578	—	15,578	D	—	—	(F1) Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, NuVasive, Inc. ("NuVasive") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into NuVasive (the "Merger"), with NuVasive continuing as a wholly owned subsidiary of the Issuer. At the effective time of the Merger, each NuVasive restricted stock unit award was accelerated, cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Issuer, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of NuVasive common stock underlying such award.
2	Derivative	Stock Option (Right to Buy Class A Common Stock)	2023-09-01	A	A	15,000	$0.00	15,000	D	$54.23 · — to 2024-09-01	15,000 Class A Common Stock	(F2) These options were granted on September 1, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on September 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.